COVID-19 Post-Infectious Encephalitis Presenting With Delirium as an Initial Manifestation.


Journal

Journal of investigative medicine high impact case reports
ISSN: 2324-7096
Titre abrégé: J Investig Med High Impact Case Rep
Pays: United States
ID NLM: 101624758

Informations de publication

Date de publication:
Historique:
entrez: 7 7 2021
pubmed: 8 7 2021
medline: 13 7 2021
Statut: ppublish

Résumé

We report the case of a 65-year-old man with COVID-19 (coronavirus disease-2019) post-infectious encephalitis who presented with delirium as an initial manifestation. He had severe COVID-19 pneumonia and recovered with dexamethasone and tocilizumab. One week after discharge, he developed abnormal behavior and delirium without fever and respiratory symptoms. Brain magnetic resonance imaging showed no abnormalities. Cerebrospinal fluid showed pleocytosis and elevated protein concentrations and was negative for severe acute respiratory syndrome-coronavirus-2 RNA. No anti-neuronal autoantibodies against intracellular and neuronal surface proteins were detected. The cerebrospinal fluid inflammatory changes compatible with post-infectious encephalitis, and the patient recovered with intravenous methylprednisolone and intravenous immunoglobulin therapy. Delirium could be an initial symptom of post-infectious encephalitis in older adults with COVID-19, and these patients may require immunosuppressive therapy.

Identifiants

pubmed: 34229469
doi: 10.1177/23247096211029787
pmc: PMC8267028
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

23247096211029787

Références

Brain. 2020 Oct 1;143(10):3104-3120
pubmed: 32637987
Neurology. 2017 Apr 4;88(14):1340-1348
pubmed: 28258082
J Neurol Neurosurg Psychiatry. 2020 Sep;91(9):1013-1014
pubmed: 32636212
J Neurol. 2021 Mar;268(3):751-757
pubmed: 32734353
Neurology. 2020 Sep 29;95(13):e1868-e1882
pubmed: 32680942
Brain Behav Immun. 2020 Aug;88:68-70
pubmed: 32531427
Lancet Neurol. 2020 Nov;19(11):919-929
pubmed: 33031735
N Engl J Med. 2020 Sep 3;383(10):989-992
pubmed: 32530583
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
J Neurol Sci. 2020 Nov 15;418:117090
pubmed: 32805440
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
Brain Behav Immun. 2021 Mar;93:415-419
pubmed: 33359380
JAMA Netw Open. 2020 Nov 2;3(11):e2029540
pubmed: 33211114

Auteurs

Makoto Hara (M)

Division of Neurology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

Kento Kouda (K)

Division of Neurology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

Tomotaka Mizoguchi (T)

Division of Neurology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

Yuki Yokota (Y)

Division of Neurology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

Kentaro Hayashi (K)

Division of Respiratory Medicine, Department of Medicine, Nihon University School of Medicine.

Yasuhiro Gon (Y)

Division of Respiratory Medicine, Department of Medicine, Nihon University School of Medicine.

Hideto Nakajima (H)

Division of Neurology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH